Ann Dermatol.  2009 Feb;21(1):27-34. 10.5021/ad.2009.21.1.27.

The Increased Expression of Matrix Metalloproteinase-9 Messenger RNA in the Non-lesional Skin of Patients with Large Plaque Psoriasis Vulgaris

• Lee SE
• Lew W

• KMID: 2172061
• DOI: http://doi.org/10.5021/ad.2009.21.1.27

Abstract

BACKGROUND
A difference of the interleukin-18 (IL-18) mRNA expression among several proinflammatory genes was previously observed between large plaque (LP) psoriasis patients (more than 5 cm lesions are typical) and small plaque (SP) psoriasis patients (1~2 cm lesions are typical). Therefore, it is necessary to test whether there is any difference in the expression of the genes that activate IL-18 or the expression of genes that are induced by IL-18.
OBJECTIVE
To test the differential mRNA expressions of caspase-1, STAT-6, MMP-1, MMP-2, MMP-9 and TIMP-1 according to the clinical types of psoriasis vulgaris lesions in Korean patients, we have analyzed the skin samples of psoriasis vulgaris patients.
METHODS
The total cellular RNA of skin samples from groups of patient with LP and SP psoriasis was analyzed by performing real-time PCR (the Taqman method) to compare the differences in the mRNA expressions.
RESULTS
The caspase-1 and STAT-6 mRNA expression levels from the SP lesional skin of the patients were increased compared with the caspase-1 and STAT-6 mRNA expression levels from SP non-lesional skin or normal skin, but these expression levels from the SP non-lesional skin were not significantly different from those of the LP non-lesional skin. Among MMP-1, MMP-2, MMP-9 and TIMP-1, the expressions of MMP-1, MMP-2 and MMP-9 mRNA were increased in the SP lesional skin compared with those of the SP non-lesional skin. The MMP-1 mRNA expressions in both the LP and SP lesional skin were increased compared with those in the normal skin (p=0.028 and p=0.007 respectively). The MMP-9 mRNA expression in the LP non-lesional skin was elevated compared with the MMP-9 mRNA expression in the SP non-lesional skin (p=0.047). The TIMP-1 mRNA expression levels from the non-lesional skin and the lesional skin of the psoriasis patients and the normal skin samples were not significantly different.
CONCLUSION
The increased expression of MMP-9 mRNA in the LP non-lesional skin compared to that of the SP non-lesional skin in the psoriatic skin suggests that the increased MMP-9 mRNA expression is related to the large size type of lesion.

Keyword

Psoriasis vulgaris; Large plaque type; Small plaque type; Matrix metalloproteinase-9

MeSH Terms

Humans
Interleukin-18
Matrix Metalloproteinase 9
Psoriasis
Real-Time Polymerase Chain Reaction
RNA
RNA, Messenger
Skin
Tissue Inhibitor of Metalloproteinase-1
Interleukin-18
Matrix Metalloproteinase 9
RNA
RNA, Messenger
Tissue Inhibitor of Metalloproteinase-1

Figure

• 

  Fig. 1 (A) The caspase-1 mRNA and (B) STAT-6 mRNA expressions in psoriatic lesions. The total cellular RNA was prepared from the non-lesional and lesional skin of four patients with large plaque (LP) psoriasis, and from the non-lesional and lesional skin of four patients with small plaque (SP) psoriasis. The mRNA was amplified for the indicated genes by performing quantitative reverse transcription-polymerase chain reaction. The levels of RNA were normalized to human acidic ribosomal protein. The mean±SD expression levels in the non-lesional and lesional skin are presented for all four patients. *Statistically significant differences (p<0.05) between the non-lesional and lesional skin (or the normal control and lesional skin) of the patients with the SP type of psoriasis. **Statistically significant differences (p<0.05) between the normal control and lesional skin of patients with the SP type of psoriasis. Empty box: normal volunteer skin, dotted box: non-lesional skin of LP psoriasis, striped box: lesion of LP psoriasis, shaded box: non-lesional skin of SP psoriasis, filled box: lesion of SP psoriasis.

• 

  Fig. 2 (A) The MMP-1, (B) MMP-2, (C) MMP-9 and (D) TIMP-1 mRNA expressions in psoriatic lesions. The total cellular RNA was prepared from the non-lesional skin and lesional skin of four patients with large plaque (LP) psoriasis, and from the non-lesional skin and lesional skin of four patients with small plaque (SP) psoriasis. The mRNA was amplified for the indicated genes by performing quantitative reverse transcription-polymerase chain reaction. The levels of RNA were normalized to human acidic ribosomal protein. The mean±SD expression levels in the non-lesional skin and lesional skin are presented for all four patients. *Statistically significant differences (p<0.05) between the non-lesional skin and lesional skin (or normal control and lesional skin) of the patients with the SP type of psoriasis; **statistically significant difference (p<0.05) between the normal control skin and the lesional skin of patients with the LP type of psoriasis; ***statistically significant differences (p<0.05) between the non-lesional skin and the lesional skin of patients with the SP type of psoriasis; ****statistically significant difference (p<0.05) between the non-lesional skin of the LP type and the non-lesional skin of the SP type; empty box: normal volunteer skin, dotted box: non-lesional skin of LP psoriasis, striped box: lesion of LP psoriasis, shaded box: non-lesional skin of SP psoriasis, filled box: lesion of SP psoriasis.

Reference

1. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007. 445:866–873.

2. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol. 1999. 113:752–759.

3. Jariwala SP. The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res. 2007. 299:359–366.

4. Terui T, Ozawa M, Tagami H. Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated inflammation-boosting loop. Exp Dermatol. 2000. 9:1–10.

5. Nickoloff BJ. Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: human skin model of psoriasis. J Investig Dermatol Symp Proc. 2000. 5:67–73.

6. Bowcock AM, Shannon W, Du F, Duncan J, Cao K, Aftergut K, et al. Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet. 2001. 10:1793–1805.

7. Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest. 2001. 81:335–347.

8. Lew W, Bowcock AM, Krueger JG. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. Trends Immunol. 2004. 25:295–305.

9. Lew W, Lee E, Krueger JG. Psoriasis genomics: analysis of proinflammatory (type 1) gene expression in large plaque (Western) and small plaque (Asian) psoriasis vulgaris. Br J Dermatol. 2004. 150:668–676.

10. Dinarello CA. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci. 1998. 856:1–11.

11. Abraham M, Shapiro S, Lahat N, Miller A. The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells. Int Immunol. 2002. 14:1449–1457.

12. Zhang B, Wu KF, Cao ZY, Rao Q, Ma XT, Zheng GG, et al. IL-18 increases invasiveness of HL-60 myeloid leukemia cells: up-regulation of matrix metalloproteinases-9 (MMP-9) expression. Leuk Res. 2004. 28:91–95.

13. Tamai K, Ishikawa H, Mauviel A, Uitto J. Interferon-gamma coordinately upregulates matrix metalloprotease (MMP)-1 and MMP-3, but not tissue inhibitor of metalloproteases (TIMP), expression in cultured keratinocytes. J Invest Dermatol. 1995. 104:384–390.

14. Hebenstreit D, Wirnsberger G, Horejs-Hoeck J, Duschl A. Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev. 2006. 17:173–188.

15. Kruse N, Pette M, Toyka K, Rieckmann P. Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. J Immunol Methods. 1997. 210:195–203.

16. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996. 6:986–994.

17. van Ruissen F, Le M, Carroll JM, van der Valk PG, Schalkwijk J. Differential effects of detergents on keratinocyte gene expression. J Invest Dermatol. 1998. 110:358–363.

18. Mauviel A. Cytokine regulation of metalloproteinase gene expression. J Cell Biochem. 1993. 53:288–295.

19. Saren P, Welgus HG, Kovanen PT. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol. 1996. 157:4159–4165.

20. Lavigne MC, Thakker P, Gunn J, Wong A, Miyashiro JS, Wasserman AM, et al. Human bronchial epithelial cells express and secrete MMP-12. Biochem Biophys Res Commun. 2004. 324:534–546.

21. Wolk K, Witte E, Wallace E, Docke WD, Kunz S, Asadullah K, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006. 36:1309–1323.

22. Opdenakker G, Van den Steen PE, Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 2001. 22:571–579.

23. Fleischmajer R, Kuroda K, Hazan R, Gordon RE, Lebwohl MG, Sapadin AN, et al. Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor TIMP-2. J Invest Dermatol. 2000. 115:771–777.

24. Suomela S, Kariniemi AL, Snellman E, Saarialho-Kere U. Metalloelastase (MMP-12) and 92-kDa gelatinase (MMP-9) as well as their inhibitors, TIMP-1 and -3, are expressed in psoriatic lesions. Exp Dermatol. 2001. 10:175–183.

25. Thewes M, Worret WI, Engst R, Ring J. Stromelysin-3 (ST-3): immunohistochemical characterization of the matrix metalloproteinase (MMP)-11 in benign and malignant skin tumours and other skin disorders. Clin Exp Dermatol. 1999. 24:122–126.

26. Suomela S, Kariniemi AL, Impola U, Karvonen SL, Snellman E, Uurasmaa T, et al. Matrix metalloproteinase-19 is expressed by keratinocytes in psoriasis. Acta Derm Venereol. 2003. 83:108–114.

27. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005. 202:135–143.

28. Nestle FO, Gilliet M. Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha. J Invest Dermatol. 2005. 125:xiv–xv.

29. Ninomiya T, Yoon S, Nagano H, Kumon Y, Seo Y, Kasuga M, et al. Significance of serum matrix metalloproteinases and their inhibitors on the antifibrogenetic effect of interferon-alfa in chronic hepatitis C patients. Intervirology. 2001. 44:227–231.

30. Flisiak I, Porebski P, Chodynicka B. Effect of psoriasis activity on metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in plasma and lesional scales. Acta Derm Venereol. 2006. 86:17–21.

31. Flisiak I, Mysliwiec H, Chodynicka B. Effect of psoriasis treatment on plasma concentrations of metalloproteinase-1 and tissue inhibitor of metalloproteinases-1. J Eur Acad Dermatol Venereol. 2005. 19:418–421.

32. Feliciani C, Vitullo P, D'Orazi G, Palmirotta R, Amerio P, Pour SM, et al. The 72-kDa and the 92-kDa gelatinases, but not their inhibitors TIMP-1 and TIMP-2, are expressed in early psoriatic lesions. Exp Dermatol. 1997. 6:321–327.

33. Nickoloff BJ, Karabin GD, Barker JN, Griffiths CE, Sarma V, Mitra RS, et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol. 1991. 138:129–140.

34. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994. 96:146–151.

35. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol. 1993. 101:701–705.

36. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol. 1994. 102:145–149.

37. Nickoloff BJ. Role of interferon-gamma in cutaneous trafficking of lymphocytes with emphasis on molecular and cellular adhesion events. Arch Dermatol. 1988. 124:1835–1843.

38. Szabo SK, Hammerberg C, Yoshida Y, Bata-Csorgo Z, Cooper KD. Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. J Invest Dermatol. 1998. 111:1072–1078.

39. Giannelli G, Brassard J, Foti C, Stetler-Stevenson WG, Falk-Marzillier J, Zambonin-Zallone A, et al. Altered expression of basement membrane proteins and their integrin receptors in lichen planus: possible pathogenetic role of gelatinases A and B. Lab Invest. 1996. 74:1091–1104.

40. Niimi Y, Pawankar R, Kawana S. Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid. Int Arch Allergy Immunol. 2006. 139:104–113.

41. Cordiali-Fei P, Trento E, D'Agosto G, Bordignon V, Mussi A, Ardigo M, et al. Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-alpha. J Autoimmune Dis. 2006. 3:5.

42. Cordiali-Fei P, Trento E, D'Agosto G, Bordignon V, Mussi A, Ardigo M, et al. Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. Ann N Y Acad Sci. 2007. 1110:578–589.

43. Papathoma AS, Zoumpourlis V, Balmain A, Pintzas A. Role of matrix metalloproteinase-9 in progression of mouse skin carcinogenesis. Mol Carcinog. 2001. 31:74–82.

44. Itoh T, Tanioka M, Matsuda H, Nishimoto H, Yoshioka T, Suzuki R, et al. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis. 1999. 17:177–181.